We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Debiopharm and Solid Biosciences Announces Collaboration
News

Debiopharm and Solid Biosciences Announces Collaboration

Debiopharm and Solid Biosciences Announces Collaboration
News

Debiopharm and Solid Biosciences Announces Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Debiopharm and Solid Biosciences Announces Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Debiopharm International SA (Debiopharm) and Solid Biosciences, LLC have announced the start of preclinical studies of Alisporivir, in the rare disease Duchenne Muscular Dystrophy (DMD). The objective of the collaboration is to reinforce existing preclinical proof of concept data in additional DMD animal models. This preclinical work, fully funded by the Lausanne-based company, will then lead to Debiopharm initiating the clinical development of this new and promising therapeutic for DMD at its own expense in the near future.

Alisporivir is a non-immunosuppressive cyclophilin inhibitor, with multiple potential indications and has already been tested in more than 1500 patients during clinical development for hepatitis C, demonstrating an acceptable safety profile.

Alisporivir is able to prevent mitochondrial-dependent muscular cell death and has shown promising activity in preclinical models of DMD but also Limb-Girdle and Ullrich-Bethlem myopathy. The aim of this collaboration is to confirm the efficacy of the compound in a new model of DMD that more closely resembles the human pathology and to enable the start of clinical development in this indication.

“We are delighted to start development in muscular dystrophy”, said Thierry Mauvernay, Delegate of the Board of Debiopharm Group. He added: “We are very pleased to be able to work with Solid Biosciences on this program, combining our deep understanding of Alisporivir with their great expertise and network in DMD and their focus on finding solutions for these young patients suffering from this terrible disease.”

“We, at Solid Biosciences, are proud to be partnering with Debiopharm”, said Ilan Ganot, founder and CEO of Solid Biosciences. “Alisporivir has exciting efficacy potential in DMD and we look forward to put to work our expertise in this condition to help advance Alisporivir to patients afflicted with DMD. I am particularly grateful to Bob McDonald and Ed Mascioli whose personal and professional commitment to DMD patients is reflected in this relationship.”

Advertisement